News ++ Press Releases

April 25, 2022 | Biotheryx

Biotheryx Announces Appointment of Jeff Caravella as Chief Financial Officer

Mr. Caravella has more than 20 years of healthcare finance experience, including at Tango Therapeutics and Johnson & Johnson SAN[…] Read More

February 23, 2022 | Biotheryx

BioTheryX Appoints Nancy Miller-Rich as Chair of Its Board of Directors

Ms. Miller-Rich brings over 35 years of biopharma leadership experience, including senior roles at Merck & Co. and Schering-Plough David[…] Read More

January 26, 2022 | Biotheryx

BioTheryX Doses First Patient in Phase 1 Study Investigating Lead Protein Degrader Candidate BTX-1188

Study to Evaluate the Safety, Pharmacokinetics and Preliminary Efficacy of BTX-1188 in Patients with Advanced Hematologic and Solid Tumor Malignancies[…] Read More

January 20, 2022 | Biotheryx

BioTheryX Announces Appointment of Sahm Nasseri as Chief Business Officer

SAN DIEGO, Jan. 20, 2022 — BioTheryX, Inc., a clinical-stage company focused on targeted protein degradation to create life-saving medicines,[…] Read More

November 2, 2021 | Biotheryx

BioTheryX Receives IND Clearance from FDA to Proceed with Phase 1 Study of BTX-1188, a Molecular Glue, for the Treatment of Hematologic and Solid Malignancies

Enrollment for Phase 1 Clinical Trial to Commence by End of 2021 SAN DIEGO, Nov. 2, 2021 /PRNewswire/ — BioTheryX,[…] Read More

October 28, 2021 | Biotheryx

BioTheryX Announces Appointment of Philippe Drouet as Chief Executive Officer

SAN DIEGO, Oct. 28, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on targeted protein degradation to create life-saving[…] Read More

August 6, 2021 | Biotheryx

BioTheryX Announces Appointments of Three New Members to its Board of Directors

SAN DIEGO, Aug. 6, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on creating life-saving medicines through targeted protein[…] Read More

June 9, 2021 | Biotheryx

BioTheryX Announces First Patient Dosed with BTX-A51 in Phase 1 Clinical Trial in Patients with Advanced Solid Tumors

SAN DIEGO, June 9, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More

May 25, 2021 | Biotheryx

BioTheryX to Present at the 2021 Jefferies Virtual Healthcare Conference

SAN DIEGO, May 25, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More

May 20, 2021 | Biotheryx

BioTheryX Announces $92M Series E Financing to Accelerate Development of Targeted Protein Degradation Pipeline and Technology Platform in Oncology

First molecular glue program, BTX-1188, expected to enter the clinic by the end of 2021 Additional protein degradation programs on[…] Read More

May 18, 2021 | Biotheryx

BioTheryX Announces Expansion of Scientific Advisory Board with Appointment of Brenda Schulman

SAN DIEGO, May 18, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More

May 4, 2021 | Biotheryx

BioTheryX to Present at 2021 RBC Capital Markets Global Healthcare Conference

SAN DIEGO, May 4, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More

April 7, 2021 | Biotheryx

BioTheryX Announces Expansion of Scientific Advisory Board

SAN DIEGO, April 7, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More

March 3, 2021 | Biotheryx

BioTheryX to Present at the Barclays Global Healthcare Conference and the Credit Suisse Solebury Trout Healthcare Innovators Conference

SAN DIEGO, March 3, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More

February 15, 2021 | Biotheryx

BioTheryX to Participate in Upcoming Scientific and Investor Events

SAN DIEGO, Feb. 15, 2021 /PRNewswire/ —┬áBioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines, today[…] Read More

February 1, 2021 | Biotheryx

BioTheryX Appoints Jamie Donadio as Chief Financial Officer

SAN DIEGO, Jan. 7, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More

January 7, 2021 | Biotheryx

BioTheryX Appoints Robert F. Williamson, III as President and Chief Executive Officer

SAN DIEGO, Jan. 7, 2021 /PRNewswire/ — BioTheryX, Inc., a clinical-stage company focused on degrading proteins to create life-saving medicines,[…] Read More

July 28, 2020 | Biotheryx

BioTheryX Announces $35 Million Series D Financing

SAN DIEGO, CA, July 28, 2020 — BioTheryX, Inc., a clinical stage biotechnology company harnessing the power of protein modulation[…] Read More

March 6, 2020 | Biotheryx

BioTheryX, Inc. Announces the Appointment of Professor Yinon Ben- Neriah, M.D., Ph.D., to its Scientific Advisory Board

Accomplished scientist who created BioTheryX’s promising lead clinical candidate targeting AML adds significant expertise in oncology & immunology to distinguished[…] Read More

January 16, 2020 | Biotheryx

BioTheryX Announces the Initiation of Patient Dosing in a First-in-Man Phase 1 Clinical Trial of BTX-A51

Study is evaluating the safety/tolerability of BTX-A51 in patients with relapsed/refractory acute myeloid leukemia (AML), as well as high risk[…] Read More

November 11, 2019 | Biotheryx

BioTheryX, Inc. Announces the Appointment of BioPharma Finance Veteran Peter N. Crnkovich to Board of Directors

Part of BioTheryX’s previously announced plan to continue building out its Board of Directors with key industry leaders now that[…] Read More

September 18, 2019 | Biotheryx

BioTheryX, Inc. Announces the Appointment of Biopharma Veteran Jeffrey L. Edwards to Board of Directors

BioTheryX plans to continue building out Board of Directors with key biopharma industry leaders as Company transitions from preclinical to[…] Read More

May 29, 2019 | Biotheryx

BioTheryX Announces FDA Approval of IND Application to Initiate Phase 1 Clinical Trial in Relapsed or Refractory Acute Myeloid Leukemia

Expect Enrollment of Phase 1 Trial to Begin in the Third Quarter of 2019 CHAPPAQUA, N.Y., May 29, 2019 /PRNewswire/[…] Read More

August 26, 2018 | Biotheryx

A promising cure for acute leukemia may be within reach

Israel 21c, August 26, 2018 Read Story

August 24, 2018 | Biotheryx

For first time in 40 years, cure for acute leukemia within reach

EurekAlert, AAAS, August 24, 2018 Read Story

September 8, 2016 | Biotheryx

BioRap and BioTheryX Sign Strategic Collaborative Agreement for the Development of Novel Protein Degradation Compounds for the Treatment of Cancer and Immune Disorder

CHAPPAQUA, N.Y., Sept. 08, 2006 /PRNewswire/ — BioTheryX, Inc. (BTX), is developing next-generation drugs that selectively regulate the stability of[…] Read More

May 4, 2016 | Biotheryx

Yissum and BioTheryX Sign Licensing Agreement for the Development of Next-Generation Protein Degradation and Immunomodulatory Treatment for Hematological Cancers

CHAPPAQUA, N.Y., May 04, 2016 /PRNewswire/ — Yissum Research Development Company of the Hebrew University of Jerusalem announced today that[…] Read More

November 30, 2010 | Biotheryx

The Leukemia & Lymphoma Society® Provides Equity Financing to BioTheryX, Inc. to Accelerate Drug Development for Blood Cancer

WHITE PLAINS, N.Y. and CHAPPAQUA, N.Y., Nov. 30, 2010 /PRNewswire/ — The Leukemia & Lymphoma Society (LLS) and BioTheryX, Inc.[…] Read More